• EMA’s CHMP backed EU marketing authorization for Biocon Biologics’ pertuzumab biosimilar Pebrilzo for HER2-positive breast cancer.
• European Commission to issue the final decision; the drug cannot be marketed in the EU until authorization is granted.
• Pebrilzo is positioned as the first monoclonal antibody biosimilar to win a CHMP recommendation under EMA’s tailored clinical approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocon Biologics Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 9AQ42RMPLL4SG54M) on September 21, 2026, and is solely responsible for the information contained therein.